哌拉西林-他唑巴坦对产超广谱β-内酰胺酶大肠埃希菌和克雷伯菌属的CLSI药敏折点的临床相关性
Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.
作者信息
Gavin Patrick J, Suseno Mira T, Thomson Richard B, Gaydos J Michael, Pierson Carl L, Halstead Diane C, Aslanzadeh Jaber, Brecher Stephen, Rotstein Coleman, Brossette Stephen E, Peterson Lance R
机构信息
Evanston Northwestern Healthcare, IL 60201, USA.
出版信息
Antimicrob Agents Chemother. 2006 Jun;50(6):2244-7. doi: 10.1128/AAC.00381-05.
Abstract
We assessed infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 mug/ml. All six urinary infections responded to treatment regardless of susceptibility.
摘要
我们评估了用哌拉西林-他唑巴坦治疗的产超广谱β-内酰胺酶的大肠杆菌或克雷伯菌属引起的感染，以确定药敏折点是否能预测治疗结果。11例由敏感菌株引起的非泌尿系统感染中有10例治疗成功，6例最低抑菌浓度>16/4μg/ml的感染中有2例治疗成功。所有6例泌尿系统感染无论药敏情况如何均对治疗有反应。
相似文献
1
Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.哌拉西林-他唑巴坦对产超广谱β-内酰胺酶大肠埃希菌和克雷伯菌属的CLSI药敏折点的临床相关性
Antimicrob Agents Chemother. 2006 Jun;50(6):2244-7. doi: 10.1128/AAC.00381-05.
2
Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.从医院感染暴发中分离出的耐哌拉西林/他唑巴坦产酸克雷伯菌的特征分析
PLoS One. 2015 Nov 5;10(11):e0142366. doi: 10.1371/journal.pone.0142366. eCollection 2015.
3
Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.产超广谱β-内酰胺酶肠杆菌科细菌治疗的抗生素政策与处方策略：哌拉西林-他唑巴坦的作用
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:181-4. doi: 10.1111/j.1469-0691.2007.01864.x.
4
Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.比较产超广谱β-内酰胺酶和不产超广谱β-内酰胺酶大肠埃希菌分离株的接种物效应对阿莫西林克拉维酸和哌拉西林他唑巴坦抗菌活性的影响。
Clin Microbiol Infect. 2010 Feb;16(2):132-6. doi: 10.1111/j.1469-0691.2009.02893.x. Epub 2009 Jul 15.
5
Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.产超广谱β-内酰胺酶肠杆菌科细菌对厄他培南、美罗培南以及含与不含克拉维酸的哌拉西林-他唑巴坦的敏感性。
Chemotherapy. 2007;53(3):185-9. doi: 10.1159/000100516. Epub 2007 Mar 7.
6
Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.对于产超广谱β-内酰胺酶菌血症患者，与哌拉西林-他唑巴坦相比，碳青霉烯类治疗与生存率提高相关。
Clin Infect Dis. 2015 May 1;60(9):1319-25. doi: 10.1093/cid/civ003. Epub 2015 Jan 13.
7
Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.产超广谱β-内酰胺酶肺炎克雷伯菌和大肠埃希菌的抗菌药敏性
Isr Med Assoc J. 2005 May;7(5):298-301.
8
The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.哌拉西林/他唑巴坦的广泛使用对侵袭性大肠埃希菌和肺炎克雷伯菌分离株抗生素耐药性选择的影响。
Int J Infect Dis. 2013 Aug;17(8):e638-43. doi: 10.1016/j.ijid.2013.01.030. Epub 2013 Mar 21.
9
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).头孢洛扎/他唑巴坦对欧洲和美国医院腹腔内和尿路感染分离的需氧革兰氏阴性菌的活性检测（2012 年）。
J Infect. 2014 Sep;69(3):266-77. doi: 10.1016/j.jinf.2014.04.004. Epub 2014 Apr 26.
10
Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.希腊一家三级护理医院实施限制政策后，肺炎克雷伯菌和大肠埃希菌临床分离株对第三代和第四代头孢菌素以及哌拉西林/他唑巴坦耐药模式变化的差异。
Int J Antimicrob Agents. 2007 Jan;29(1):34-8. doi: 10.1016/j.ijantimicag.2006.08.042.
引用本文的文献
1
Shared Clavulanate and Tazobactam Antigenic Determinants Activate T-Cells from Hypersensitive Patients.克拉维酸和他唑巴坦共同抗原决定簇激活超敏患者的 T 细胞。
Chem Res Toxicol. 2022 Nov 21;35(11):2122-2132. doi: 10.1021/acs.chemrestox.2c00231. Epub 2022 Sep 22.
2
Pharmacokinetics of ceftriaxone-tazobactam (8:1) combination in healthy and induced diarrhoeic birds.头孢曲松-他唑巴坦（8:1）组合在健康和诱导腹泻禽类中的药代动力学
ADMET DMPK. 2022 Sep 13;10(3):180-196. doi: 10.5599/admet.1170. eCollection 2022.
3
Routine Intraoperative Bacterial Culture May Be Needed in Complicated Appendicitis.复杂阑尾炎可能需要常规术中细菌培养。
Ann Coloproctol. 2020 Jun;36(3):155-162. doi: 10.3393/ac.2019.11.04.1. Epub 2020 Jun 30.
4
Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant .头孢他啶-阿维巴坦治疗耐碳青霉烯类以外的多重耐药革兰阴性菌感染的临床经验
Antibiotics (Basel). 2020 Feb 9;9(2):71. doi: 10.3390/antibiotics9020071.
5
Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.哌拉西林-他唑巴坦与碳青霉烯类药物治疗产超广谱β-内酰胺酶肠杆菌科细菌所致非菌血症性尿路感染的比较
Hosp Pharm. 2020 Feb;55(1):44-49. doi: 10.1177/0018578718817933. Epub 2018 Dec 7.
6
Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?哌拉西林他唑巴坦治疗产超广谱β-内酰胺酶的生物体引起的肾盂肾炎有效吗？
Clin Infect Dis. 2020 Nov 5;71(8):e331-e337. doi: 10.1093/cid/ciz1205.
7
Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms.正反方观点：哌拉西林他唑巴坦应被用于治疗产超广谱β-内酰胺酶阳性菌感染。
J Clin Microbiol. 2018 Feb 22;56(3). doi: 10.1128/JCM.01917-17. Print 2018 Mar.
8
Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌社区获得性血流感染经验性治疗适宜性对碳青霉烯类药物确定性治疗结局的影响。
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2093-2100. doi: 10.1007/s10096-017-3031-7. Epub 2017 Jun 23.
9
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.哌拉西林-他唑巴坦、头孢吡肟和厄他培南治疗产超广谱β-内酰胺酶大肠埃希菌所致尿路感染的随机对照试验
BMC Infect Dis. 2017 Jun 7;17(1):404. doi: 10.1186/s12879-017-2502-x.
10
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.非碳青霉烯类β-内酰胺类药物在治疗产超广谱β-内酰胺酶感染中的应用
Clin Infect Dis. 2017 Apr 1;64(7):972-980. doi: 10.1093/cid/cix034.
本文引用的文献
1
The inoculum effect: fact or artifact?接种物效应：事实还是假象？
Diagn Microbiol Infect Dis. 2004 Dec;50(4):229-30. doi: 10.1016/j.diagmicrobio.2004.07.006.
2
Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.通过使用群体药代动力学模型和蒙特卡洛模拟对患者在他唑巴坦存在的情况下哌拉西林的药效学特征进行分析。
Antimicrob Agents Chemother. 2004 Dec;48(12):4718-24. doi: 10.1128/AAC.48.12.4718-4724.2004.
3
Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌引起的血流感染：死亡率和治疗结果的危险因素，特别强调抗菌治疗。
Antimicrob Agents Chemother. 2004 Dec;48(12):4574-81. doi: 10.1128/AAC.48.12.4574-4581.2004.
4
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.肺炎克雷伯菌菌血症的抗生素治疗：超广谱β-内酰胺酶产生的影响
Clin Infect Dis. 2004 Jul 1;39(1):31-7. doi: 10.1086/420816. Epub 2004 Jun 8.
5
Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.抗菌药物的基本药效学及其在β-内酰胺类、糖肽类和利奈唑胺临床应用中的情况。
Infect Dis Clin North Am. 2003 Sep;17(3):479-501. doi: 10.1016/s0891-5520(03)00065-5.
6
Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period.某医院两年期间产超广谱β-内酰胺酶菌株的临床与微生物学分析
Pharmacotherapy. 2003 Oct;23(10):1232-7. doi: 10.1592/phco.23.12.1232.32706.
7
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.头孢吡肟和哌拉西林-他唑巴坦对产超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌菌株的药代动力学-药效学：ARREST项目报告
Antimicrob Agents Chemother. 2003 May;47(5):1643-6. doi: 10.1128/AAC.47.5.1643-1646.2003.
8
Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.产超广谱β-内酰胺酶（ESBL）的肠杆菌科细菌：诊断、预防及药物治疗的相关考量
Drugs. 2003;63(4):353-65. doi: 10.2165/00003495-200363040-00002.
9
Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.囊性纤维化患者间歇性或持续输注哌拉西林期间非线性行为的群体药代动力学分析。
Antimicrob Agents Chemother. 2003 Feb;47(2):541-7. doi: 10.1128/AAC.47.2.541-547.2003.
10
Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.儿童产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌血流感染：流行病学及临床结局
Antimicrob Agents Chemother. 2002 May;46(5):1481-91. doi: 10.1128/AAC.46.5.1481-1491.2002.
Zotero 插件